IMS 2023 | AL amyloidosis special session highlights: therapeutic advances and ongoing trials in the field
Vaishali Sanchorawala
• 29 Sep 2023
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, gives an overview of therapeutic advances made in the field of light chain (AL) amyloidosis, commenting on novel anti-fibril agents being explored. Prof. Sanchorawala shares insights into ongoing trials exploring these novel agents, including the AFFIRM-AL trial and the CAEL-101 trial (NCT04973137; NCT04512235). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
